Drugs / 89Zr-NY005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04989010 | Aug 2021 → Aug 2022 | cancer | Wuxi No. 4 People's Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-NY005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04989010 ↗ |
| Modality | Monoclonal antibody | “89Zr-labeled anti-CLDN18.2 mAbs (89Zr-NY005)” NCT04989010 ↗ |
| Route | Intravenous | “Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3 mCi) labeled anti-CLDN18.2 mAbs (89Zr-NY005)” NCT04989010 ↗ |